Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study
Matsukawa Y, Naito Y, Funahashi Y, Ishida S, Fujita T
Published in Neurourology and Urodynamics
Methodology
Randomised prospective trial in 100 men with chronic prostatitis/chronic pelvic pain syndrome refractory to alpha-1 blocker monotherapy, comparing add-on cernitin pollen extract (4 capsules/day) with tadalafil 5 mg/day for 12 weeks.
Key Findings
Cernitin produced greater improvement than tadalafil in NIH-CPSI total score (-6.8 vs -4.6; P=.02) and pain sub-score (-4.1 vs -1.5; P<.001), while tadalafil was superior for lower urinary tract symptoms.
Conclusions
Cernitin pollen extract is an effective add-on option for pain in refractory chronic prostatitis/chronic pelvic pain syndrome.
Limitations
Open comparison without placebo arm, single-country cohort, cernitin is a standardised grass pollen extract rather than raw bee pollen.
Supplements Studied
The cernitin (vs tadalafil) group showed significantly greater improvements in the NIH-CPSI total score (-6.8 vs -4.6; P = .02) and NIH-CPSI pain sub-score (-4.1 vs -1.5; P < .001).
Outcomes Measured
Although the NIH-CPSI total, NIH-CPSI pain sub-score, and NIH-CPSI quality of life sub-score significantly improved in both groups, the cernitin (vs tadalafil) group showed significantly greater improvements.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.